Brooks Laboratories LimitedBROOKSCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data

₹67.57

MCap ₹199 Cr · P/E 43.6

Brooks Laboratories Limited — Stock analysis & AI research Brooks Laboratories Limited — Seasonality — best & worst months Brooks Laboratories Limited — Technical setup — score, trend, support & resistance Brooks Laboratories Limited — Live exchange announcements

📈 Stocks Above Anchored VWAP 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹23 Cr

Sales · Jun 2026

-10.0% YoY

₹2 Cr

Operating Profit · Jun 2026

-40.4% YoY

8.1%

OPM % · Jun 2026

-34.1% YoY

₹1 Cr

Net Profit · Jun 2026

-46.5% YoY

₹0.48

EPS · Jun 2026

-46.7% YoY

📝 Brooks Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Brooks Laboratories Limited reported revenue of ₹23 crore for the quarter ended June 2026 (Q1 FY27), down 10.0% from ₹26 crore in the same quarter last year, and up 13.6% sequentially over the March 2026 quarter.

Net profit fell 46.5% year-on-year to ₹1 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.48.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 8.1%, compared with 12.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Brooks Laboratories Limited posted revenue of ₹86 crore, a decline of 14.7% over FY25, with a net profit of ₹6 crore (up 103.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹83 crore with a net profit of ₹5 crore.

Valuation snapshot

At the current price of ₹67.57, BROOKS has a market capitalisation of ₹199 crore and a trailing P/E of about 43.6.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 52.62%, foreign institutional investors (FIIs) 0.17%, domestic institutional investors (DIIs) 10.38%, public shareholders 36.84% of Brooks Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹199 Cr

Current Price ?

₹67.6

P/E ?

43.57above ind

Industry P/E ?

37.20

P/B ?

1.65

P/S ?

2.39

P/FCF ?

32.85

Enterprise Value ?

₹208 Cr

EV/EBITDA ?

35.80

PEG ?

1.12

Earnings Yield ?

2.0%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹83 Cr

OPM ?

7.0%

Profit after tax (TTM) ?

₹5 Cr

EPS (TTM) ?

₹1.55

ROCE ?

5.3%

ROE ?

3.8%

ROA ?

3.1%

Growth

Sales — latest qtr ?

₹23 Cr

PAT — latest qtr ?

₹1 Cr

YoY qtr sales growth ?

-10.0%

YoY qtr profit growth ?

-46.5%

Sales growth (3y) ?

16%

Sales growth (5y) ?

Profit growth (3y) ?

39%

Profit growth (5y) ?

19%

Financial Health

Debt ?

₹9 Cr

Debt to Equity ?

0.07

Interest Coverage ?

6.5

Current Ratio ?

N/A

Ownership

Promoter holding ?

52.62%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-2.7%

Return 6 months ?

-0.0%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	12	13	16	24	22	18	18	21	38	23	26	23	17	20	23	-10.0%	+13.6%
Operating Profit	-1	-0	0	2	1	0	0	2	2	2	3	3	1	1	2	-40.4%	+173.9%
Other Income	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	-18.6%	-59.8%
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-31.8%	+128.3%
Depreciation	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	+6.0%	+1.3%
Profit Before Tax	-2	-1	-1	1	1	0	-0	1	1	2	3	2	0	1	1	-46.5%	+128.8%
Net Profit	-2	-1	-1	1	1	0	-0	1	1	1	3	2	0	1	1	-46.5%	+132.6%
EPS	-0.84	-0.27	-0.20	0.46	0.23	0.11	-0.08	0.37	0.28	0.51	0.90	0.76	0.10	0.21	0.48	-46.7%	+128.6%
OPM %	-12.3%	-1.0%	0.2%	7.1%	5.0%	2.1%	1.6%	7.3%	4.8%	6.8%	12.3%	10.8%	4.4%	3.4%	8.1%	-34.1%	+138.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹100 Cr	₹86 Cr	₹83 Cr	-14.7%
Operating Profit	₹5 Cr	₹7 Cr	₹6 Cr	+35.2%
OPM %	5.20%	8.24%	6.97%	+58.5%
NPM %	2.83%	6.77%	5.49%	+139.2%
Other Income	₹1 Cr	₹1 Cr	₹1 Cr	+18.8%
Depreciation	₹2 Cr	₹2 Cr	₹2 Cr	-20.7%
Interest	₹1 Cr	₹1 Cr	₹1 Cr	-29.6%
EBIT	₹3 Cr	₹5 Cr	₹4 Cr	+70.0%
PBT	₹3 Cr	₹6 Cr	₹5 Cr	+92.4%
Tax	₹0 Cr	—	—	—
Net Profit	₹3 Cr	₹6 Cr	₹5 Cr	+103.9%
EPS	₹1.08	₹1.97	₹1.55	+82.4%
Material Cost	₹54 Cr	₹40 Cr	₹38 Cr	-26.5%
Employee Cost	₹13 Cr	₹11 Cr	₹12 Cr	-11.8%
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	24.70	26.25	29.46	29.46	+0.0%
Reserves	32.08	43.28	85.61	91.39	+6.8%
Borrowings	6.51	5.64	7.58	8.52	+12.4%
Other Liabilities	29.13	19.22	18.01	16.99	-5.7%
Total Liabilities	92.42	94.39	140.66	146.36	+4.1%
Fixed Assets	15.01	13.67	13.98	14.52	+3.9%
CWIP	0.00	0.00	0.00	1.19	—
Investments	46.85	46.86	90.52	90.53	+0.0%
Other Assets	30.56	33.86	36.16	40.12	+11.0%
Total Assets	92.42	94.39	140.66	146.36	+4.1%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	0.55	-9.80	2.63	9.29	+253.2%
Cash from Investing Activity	-0.40	0.18	-45.14	-2.92	+93.5%
Cash from Financing Activity	-0.21	9.72	42.43	0.17	-99.6%
Net Cash Flow	-0.06	0.10	-0.08	6.54	+8275.0%
Free Cash Flow	0.08	-10.24	1.72	6.06	+252.3%
CFO/OP	-13%	-308%	43%	131%	+204.7%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	83.79	74.94	88.38	68.58	-22.4%
Inventory Days	99.41	60.49	60.56	78.84	+30.2%
Days Payable	205.59	97.25	89.65	81.84	-8.7%
Cash Conversion Cycle	-22.39	38.18	59.28	65.58	+10.6%
Working Capital Days	-42.65	33.57	43.28	34.31	-20.7%
ROCE %	-11.07%	3.45%	4.29%	5.27%	+22.8%

👥 Shareholding (latest 4 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	52.62%	52.62%	52.62%	52.62%	+0.0%
FIIs	0.00%	0.01%	0.09%	0.17%	+88.9%
DIIs	10.38%	10.38%	10.38%	10.38%	+0.0%
Public	37.00%	37.00%	36.91%	36.84%	-0.2%
No. of Shareholders	10,317	10,078	10,532	10,741	+2.0%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	BROOKS Brooks Laboratories	₹61.02	180	13.6	83	13	7.0%	15.9%	-14.7%	298.2%	-10.0%	-118.6%

❓ Frequently asked questions

What was Brooks Laboratories Limited's revenue in Q1 FY27?

What was Brooks Laboratories Limited's net profit in Q1 FY27?